The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Improving cancer pain control: Potential impact of CYP2D6 pharmacogenomic (PGx) testing in oncology (Onc) patients.
 
Natalie Reizine
No Relationships to Disclose
 
Keith Danahey
No Relationships to Disclose
 
Emily Schierer
No Relationships to Disclose
 
Tien Truong
No Relationships to Disclose
 
Mark J. Ratain
Consulting or Advisory Role - Aptevo Therapeutics; Ascentage Pharma; Cyclacel; Shionogi
Research Funding - Abbvie (Inst); Dicerna (Inst); Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - pending patent related to a genomic prescribing system; pending patent related to a genomic prescribing system (Inst); royalties related to UGT1A1 genotyping for irinotecan; royalties related to UGT1A1 genotyping for irinotecan (Inst)
Expert Testimony - multiple generic companies
Other Relationship - BeiGene; Value in Cancer Care Consortium
 
Peter H. O'Donnell
Honoraria - Astellas Pharma; Atheneum; Dedham Group; FirstWord; Genentech/Roche; Health Advances; Janssen; Merck; OncLive; Schlesinger Associates; Seagen
Consulting or Advisory Role - Merck
Research Funding - Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Janssen (Inst); Merck (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Janssen; Janssen; Merck; Seattle Genetics/Astellas
Other Relationship - Janssen; Nektar; NIH